TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29959787
Drug: Elobixibat 5
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 5 mg
Study: 28840422
Drug: Elobixibat 10
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 10 mg
Study: 28840422
Drug: Elobixibat 15
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 15 mg
Study: 29959787
Drug: Elobixibat 20
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 20 mg
Study: 26378033
Drug: Imatinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (200 mg daily)
Study: 26378033
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months)
Study: 25454967
Drug: Acupoint pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint pressure therapy (APT)
Study: 25454967
Drug: Collateral meridian
Normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collateral meridian therapy (CMT)
Study: 20569776
Drug: Unassisted bibliotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unassisted bibliotherapy (n=20) with a scheduled follow‐up telephone interview, no therapist contact, treatment phase lasted for 10 weeks.
Study: 18723851
Drug: Nitroglycerin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin administration during head-up tilt test (HUT)
Study: 18723851
Drug: Head-up tilt
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-up tilt test without nitroglycerin administration
Study: 18723851
Drug: Head-up tilt
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-up tilt test before nitrate administration
Study: 15709995
Drug: Beidellitic montmorillonite
Normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beidellitic montmorillonite (3 g, t.d. for 8 weeks)
Study: 11799340
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 to 6.0 mg/day, median dose 2.5 mg/day)
Study: 20856184
Drug: venlafaxine extended
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine extended release (75 to 325 mg daily)
Study: 10189453
Drug: Anticholinergic agent
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic agent
Study: 1326708
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate (E2V)
Study: 1326708
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate combined with 1 mg cyproterone acetate (E2V+CPA)
Study: 16359587
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment
Study: 26999966
Drug: Corticosteroids (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (40 mg methylprednisolone)
Study: 21252702
Drug: Alcohol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.0 g/kg body weight)
Study: 17063660
Drug: Small-particle formulations
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-particle formulations of ICSs
Study: 17063660
Drug: Reduced oropharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced oropharyngeal deposition and prodrug administration
Study: 10953973
Drug: Dose-escalated CHOP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated CHOP (6 cycles with cyclophosphamide 1.5 g/m2 and doxorubicin 70 mg/m2)
Study: 3286363
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of acarbose
Study: 29685011
Drug: Glucocorticoids in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids in combination with ursodesoxycholic acid
Study: 19888948
Drug: C.E.R.A. twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. twice every week (Q2W)
Study: 19888948
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (once weekly or Q2W)
Study: 16102549
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch (20 microg EE/day)
Study: 16102549
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (30 microg EE)
Study: 7631288
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb 761) administered orally while fasting
Study: 7631288
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb 761) administered orally after a standard meal
Study: 7631288
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb 761) administered intravenously
Study: 2921098
Drug: Simvastatin (MK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (MK 733) 20 mg and 40 mg daily for 104 weeks
Study: 22132709
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine plus bepanthenol cream (standard practice)
Study: 15089819
Drug: tolterodine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine (2 mg, BID) + duloxetine (40 mg, BID)
Study: 15089819
Drug: tolterodine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine (2 mg, BID) + duloxetine placebo (BID)
Study: 9587128
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate tablets (45 mg, three times a day)
Study: 9587128
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (three times a day)
Study: 2669092
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g L-tryptophan
Study: 2669092
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g L-tryptophan
Study: 2669092
Drug: L-tryptophan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (both doses)
Study: 23616514
Drug: L-tryptophan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (all doses)
Study: 23903649
Drug: Control (original‐lesion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (original‐lesion control, intra‐oral controls)
Study: 22153532
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1 g bid for 10 days)
Study: 22153532
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium bicarbonate 1 g bid for 10 days)
Study: 19898719
Drug: Acetone-containing bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetone-containing bonding agent (control group)
Study: 17998456
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg twice daily (group 1)
Study: 17998456
Drug: Enoxaparin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg twice daily (group 2)
Study: 17998456
Drug: Warfarin continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin continued (group 3)
Study: 14726422
Drug: Glutathione aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione aerosol (300 or 450 mg, thrice daily for 14 days)
Study: 12487386
Drug: Antiretroviral therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapies prescribed as part of the trial
Study: 12487386
Drug: Adverse clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse clinical events (e.g., dermatological, gastrointestinal symptoms)
Study: 9772328
Drug: Concomitant vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant vaccination (both vaccines administered simultaneously)
Study: 9772328
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine (single injection of both vaccines mixed)
Study: 9772328
Drug: Monovalent vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccines (each vaccine administered alone)
Study: 2590611
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg intravenous)
Study: 2590611
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate (600 mg intravenous)
Study: 2590611
Drug: Vehicle (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control for aspirin infusion)
Study: 184978
Drug: ACTH gel
Normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH gel (80 units once weekly or 80 units twice weekly)
Study: 31610099
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (10 mg rivaroxaban tablet)
Study: 31331789
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg up to 150 mg every 2 weeks for COMBO I & II or 150 mg every 2 weeks for LONG TERM)
Study: 28481893
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (augmented treatment as usual)
Study: 19195785
Drug: CR-oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR-oxycodone
Study: 12643328
Drug: PEG-Hirudin (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Hirudin (i.v. bolus of 0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Study: 12643328
Drug: ASA (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (325 mg)
Study: 12643328
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of ASA and PEG-Hirudin
Study: 12643328
Drug: PEG-Hirudin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Hirudin (0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Study: 22300506
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 mcg/day
Study: 22300506
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000 mcg/day
Study: 22300506
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 mcg/day and 1000 mcg/day
Study: 15598978
Drug: Prolonged rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times)
Study: 15598978
Drug: Standard schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard schedule (375 mg/m2 weekly x 4) followed by no further treatment
Study: 15598978
Drug: Prolonged rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times) in pretreated patients
Study: 15598978
Drug: Standard schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard schedule (375 mg/m2 weekly x 4) in pretreated patients
Study: 11777366
Drug: Long-term very
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term very low doses of prednisone
Study: 9504939
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg every eight hours)
Study: 9504939
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g every six hours)
Study: 3124618
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin
Study: 3124618
Drug: Subcutaneous buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buserelin
Study: 23953605
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg/day) + imidafenacin (0.1 mg 2 times a day)
Study: 23953605
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg/day) alone
Study: 19174069
Drug: Enteral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral diet supplements with arginine (group I)
Study: 16306030
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (nelfinavir, stavudine, didanosine, twice-daily)
Study: 16306030
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (nevirapine, didanosine, lamivudine, once-daily)
Study: 16306030
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (saquinavir, ritonavir, didanosine, lamivudine, once-daily)
Study: 7582277
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 360 mg triamcinolone intramuscularly
Study: 7582277
Drug: Placebo triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo triamcinolone followed by low-dose oral methotrexate (7.5 mg followed by 15 mg weekly)
Study: 1932648
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus, followed by 2 mg/min infusion)
Study: 1932648
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline bolus and infusion)
Study: 26348767
Drug: Cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanol (CF) intake (450 mg bi-daily for 1 month)
Study: 19732408
Drug: Regular counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular counseling and a treatment assistant
Study: 12608650
Drug: Deflazacort (DFZ)
DrugBank: Deflazacort (DB11921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deflazacort (DFZ) treatment for one year
Study: 2792658
Drug: Intravenous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol administration (0.15 g/kg)
Study: 2792658
Drug: Oral ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ethanol administration (0.15 g/kg)
Study: 2792658
Drug: Intraduodenal ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal ethanol administration (0.15 g/kg)
Study: 1017533
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate ointment
Study: 29607554
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate ointment
Study: 23617482
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bone suppression and CAD
Study: 21518596
Drug: Fondaparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (2.5 mg/d)
Study: 21518596
Drug: Nadroparin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (0.1 ml/10 kg q12 h)
Study: 17137026
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg twice a day intravenously and then orally, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Study: 17137026
Drug: Piperacillin/tazobactam 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4 g/0.5 g three times a day, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Study: 12924687
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) in a group format, 14 sessions, small groups of 4 to 6 participants
Study: 8684876
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of Oka/Merck varicella vaccine
Study: 8684876
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of Oka/Merck varicella vaccine
Study: 1654074
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (further six courses)
Study: 6222858
Drug: Moxalactam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (10 mg/kg)
Study: 6222858
Drug: Cefazolin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (10 mg/kg)
Study: 31925817
Drug: P218 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (10 mg)
Study: 31925817
Drug: P218 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (30 mg)
Study: 31925817
Drug: P218 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (100 mg)
Study: 31925817
Drug: P218 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (250 mg)
Study: 31925817
Drug: P218 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (500 mg)
Study: 31925817
Drug: P218 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (750 mg)
Study: 31925817
Drug: P218 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (1000 mg)
Study: 31925817
Drug: P218 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (250 mg) with food
Study: 31401653
Drug: Post-treatment effects
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment effects
Study: 31332901
Drug: Inhaled allergens
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled allergens
Study: 26147820
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg intranasal midazolam as premedication
Study: 23529993
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1200 mg n-3 long chain polyunsaturated fatty acids)
Study: 19077149
Drug: Laser Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser Doppler flowmetry (LDF) used to assess bone vascularity during implant insertion.
Study: 17726273
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg levodopa
Study: 11367872
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (T) 3 x 150 mg
Study: 11367872
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (R) 3 x 150 mg
Study: 9438894
Drug: Lidocaine 50
Normalized name: lidocaine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 50 mg
Study: 9438894
Drug: Lidocaine 200
Normalized name: lidocaine 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 200 mg
Study: 8288408
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg twice daily, n = 52; 50 mg twice daily, n = 16)
Study: 8288408
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg three times daily, n = 50; 60 mg three times daily, n = 16)
Study: 26613820
Drug: Clomifene citrate
Normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomifene citrate (100mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Study: 26613820
Drug: Letrozole (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Study: 20083625
Drug: Beta-blocker (metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (metoprolol succinate)
Study: 10383563
Drug: OROS amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS amitriptyline (75 mg)
Study: 10383563
Drug: IR amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR amitriptyline (25 mg every 8 h)
Study: 10383563
Drug: IR amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR amitriptyline (3x25 mg at nighttime)
Study: 20439595
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of Gardasil, Menactra, and Adacel (group A)
Study: 20439595
Drug: Nonconcomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonconcomitant administration of Gardasil, Menactra, and Adacel (group B)
Study: 16906786
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen of efavirenz, emtricitabine and tenofovir DF (administered as individual agents)
Study: 12707093
Drug: Subantimicrobial-dose doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subantimicrobial-dose doxycycline (20-mg tablets taken twice daily for 6 months)
Study: 11123824
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at 60 mg/kg divided into two doses
Study: 11123824
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at a single dose of 40 mg/kg
Study: 9181384
Drug: Amoxycillin/clavulanate (A/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (A/C) 70/10 mg/kg/day given b.i.d.
Study: 9181384
Drug: Amoxycillin/clavulanate (A/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (A/C) 60/15 mg/kg/day given t.i.d.
Study: 2418659
Drug: Bleomycin intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin intravesical instillation (60 mg on each treatment day)
Study: 2418659
Drug: Bleomycin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin + Bestatin (60 mg per day)
Study: 31849295
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (569 patients)